I. Abstract:
Breast cancer remains the second most common cause of cancer death in the United
States. Several studies have identified cohorts of women at higher than average risk to develop this disease. These are women who are exposed to high levels of endogenous or exogenous estrogens, those with a family history of breast cancer, and those who harbor benign breast disease or genetic mutations that predispose to breast cancer. In this population group, adapting a chemoprevention strategy to decrease the risk of developing overt disease is a strong consideration. To this end, tamoxifen is the most accepted agent to date. This article will describe high risk categories that predict future development of invasive breast cancer, will summarize the current available data to support the use of tamoxifen for chemoprevention, and will further discuss adverse effects of tamoxifen as well as measures to anticipate and monitor for possible adverse outcomes.
II. Introduction:
An estimated 214,640 American women will be diagnosed with breast cancer in 2006, according to American Cancer Society statistics (1) . It is the second most common cause of cancer death and the main cause of death for women aged 45-55. Women recognized to be at higher risk than the average population for the development of breast cancer have historically been identified as those associated with exposure to higher (or longer) levels or circulating estrogens, including older age, early menarche and later menopause, nulliparity, older age at first full-term pregnancy, and history of current or past use of hormonal replacement therapy (containing estrogen and progesterone) (1) . In addition, women considered at high risk include those with family history of breast cancer, personal history of previous breast biopsy(ies) or diagnosis of benign proliferative breast disease, personal history of radiation exposure, and those who harbor specific genetic mutations (BRCA1, BRCA2, p53, or PTEN), Chemoprevention as a strategy to interfere with the development of breast cancer in women with high risk scenarios is emerging as a strong consideration for women's health. In this regard, tamoxifen has currently been the most widely accepted agent, patterning after well-established data from its use in the treatment and risk-reduction of breast cancer in the adjuvant setting.
III. Tamoxifen for prevention:
Several studies have sought to identify subsets of women who would be at highest risk for the development of breast cancer. The Gail Risk model has historically been used to predict the 5-year as well as lifetime risk of developing invasive breast cancer. This is a validated prediction model using five factors: current age, age at menarche, previous breast biopsies, age at first live birth, and family history of breast cancer in first-degree relatives (2-4). A 5-year risk of 1.66% or greater strongly promotes consideration for prevention strategies. The Claus model is an additional tool which can provide an estimate of future breast cancer risk in women with strong family histories of breast cancer (5).
There are four prominent studies reported in the literature comparing tamoxifen with placebo in the prevention of breast cancer for women considered at high risk (6) . The American Breast Cancer Prevention Trial (P-1 study) sponsored by the National Surgical Adjuvant Breast and Bowel Project (NSABP) was a randomized trial of tamoxifen versus placebo in women considered at increased risk defined as: age older than 60, age between 35-59 with a Gail model prediction value at least 1.66%, or age 35 or greater with history of lobular carcinoma in situ (LCIS). The trial was terminated early after a median followup of 48 months when interim analysis established a statistically significant benefit with tamoxifen (7). There was 49% relative risk reduction and 21% absolute risk reduction of invasive breast cancer among the cohorts on tamoxifen. Furthermore, an update of this study showed a 62% reduction of invasive breast cancer in the tamoxifen group but the incidence for ER-negative tumors was unchanged (8) . relative risk for non-proliferative lesions (12) , with significantly higher risk in younger individuals who were diagnosed with atypia (see Figure 2) . They concluded that family history of breast cancer, defined as at least one first degree relative diagnosed with breast cancer before age 50 or two or more relatives diagnosed with breast cancer with one being a first-degree relative (12) , portended an increased risk that was independent of the benign histology, as even nonproliferative lesions were then associated with increased relative risk (see Figure 2 , not statisticially significant). Importantly, they found no additional increase in risk for women with no family history and who had nonproliferative disease on breast biopsy (12).
Hershman et al analyzed the effectiveness of tamoxifen in the very high risk cohorts of women ages 35, 50 and 60 with Gail Risk model estimates of greater than 5%, and with atypical ductal hyperplasia, lobular carcinoma in situ, or having two or more first-degree relatives with breast cancer (13) . They found that the greatest benefit of the use of tamoxifen was seen in the cohort with atypical ductal hyperplasia in whom survival benefits were prolonged by 202, 89, and 45 days respectively, depending on age, and was deemed a cost-effective maneuver in their care. These highlight the formal description of high risk-breast lesions which would be well-served with risk reduction strategies.
Further historical data from the NSABP P-1 study have been used to examine the effect of tamoxifen treatment on the incidence of benign breast disease in women at high risk for breast cancer (14) . The relative risk of breast cancer for patients with adenosis, cyst, duct ectasia, fibrocystic disease, fibroadenoma, fibrosis, hyperplasia, or metaplasia was estimated for participants who received either tamoxifen or placebo (14) . Overall, tamoxifen reduced the risk of the development of breast cancer from these benign breast diseases by 28%, occurring predominantly in the subset of women younger than 50 years (14) . This further strengthens the rationale for the use of tamoxifen as a chemopreventive strategy.
Another cohort of women at high risk for development of breast cancer are those with BRCA mutations. Carriers of both BRCA1 and 2 have an 80% lifetime risk for breast cancer (15) . These mutations also confer a risk of cancer in the opposite breast of approximately 3% per year (16) . However, there are limited data on the benefits of tamoxifen in this situation to date (17, 18) . The P-1 trial had 19 participants with BRCA1/2 mutations who later developed breast cancer. Use of tamoxifen reduced disease in BRCA2 but not in BRCA1 carriers (17) (18) (19) . Prophylactic surgery can certainly afford women who harbor BRCA1/2 mutations a substantial reduction of risk of breast cancer (20) (21) (22) (23) . For women who wish non-surgical methods of risk reduction, however, the small sample size of patients in studies with tamoxifen as chemoprevention limits the ability to support any conclusive evidence in this regard.
V. Guidelines for Chemoprevention
The and has enrolled 20,000 postmenopausal women at high risk for the development of breast cancer (29, 30) . At this writing, data from this trial is expected and is to be presented at the 2006 American Society of Clinical Oncology meeting. Unpublished results suggest that the numbers of invasive breast cancer events were similar with both drugs, but the incidence of ductal carcinoma in situ was lower on tamoxifen (31) .
Additionally, the development of uterine cancers, deep venous thromboses, and pulmonary embolism were lower with raloxifene as compared with tamoxifen (31).
Trials utilizing other SERMs chemoprevention are ongoing (6) . These include the Raloxifene for Use in the Heart (RUTH) study (32) in which breast cancer risk is assessed and the HOT study, in which low-dose tamoxifen added to HRT seeks to guage risk reduction (33) . 
